Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Conditions
- Small Cell Lung Carcinoma
- Carcinoma, Squamous Cell of Head and Neck
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Esophagogastric Junction Neoplasms
- Carcinoma, Pancreatic Ductal
- Esophageal Squamous Cell Carcinoma
Interventions
- DRUG: paclitaxel + carboplatin
- DRUG: carboplatin + etoposide
- DRUG: gemcitabine + carboplatin
- DRUG: nab-paclitaxel (paclitaxel-albumin) + carboplatin
- DRUG: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)
- BIOLOGICAL: durvalumab
- BIOLOGICAL: tremelimumab
- DRUG: nab-paclitaxel (paclitaxel-albumin) + gemcitabine
- DRUG: cisplatin + 5-fluorouracil (5FU)
Sponsor
AstraZeneca